Comparison of Aripiprazole Versus Higher Metabolic Risk Antipsychotic Drugs on Adiposity Using MRI

• Status: Completed
• Trial end date: 2016-02-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to compare abdominal weight gain and fat distribution in people taking aripiprazole versus risperidone or quetiapine, to people not taking any of these antipsychotic medications.

• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University of British Columbia
• Collaborator: Bristol-Myers Squibb
• Treatments: Antipsychotic Agents; Aripiprazole; Quetiapine Fumarate; Risperidone

Criteria

Inclusion Criteria:

• Male or female, aged 12+ years for healthy participants or participants with bipolar disorder; or aged 15+ years for participants with non-affective psychosis.

• Recent admission to hospital for psychiatric services related to first-episode psychosis or first-episode bipolar disorder.

• Participants being treated with an antipsychotic medication principally for psychosis or for bipolar disorder.

• Participants taking aripiprazole must be taking a dose of at least 10mg/day for the duration of the study.

• Participants must have received no more than 12 weeks of total lifetime exposure to antipsychotics.

• Participants may be in- or outpatients.

• Participants able to give informed consent, or informed consent through legally authorized representative.

Exclusion Criteria:

• Previous total lifetime exposure to antipsychotics of more than 12 weeks.

• Previously diagnosed with diabetes mellitus, seizure disorders, mental retardation (IQ < 70), or pregnancy (current or within 3 months postpartum).

• Participants who have been treated/are currently being treated with mood stabilizers (paroxetine, lithium, or valproic acid). Prior or concurrent use of Selective Serotonin Reuptake Inhibitor antidepressants (other than paroxetine) is acceptable.

• Received chemotherapy for cancer treatment in the 4 weeks prior to baseline or 16-week follow-up visit.

• Participants who are not able to fluently communicate in English.

• Contraindicated for MRI scan (i.e., has had major surgery in the last 6 months, morbid obesity, claustrophobia, and/or has metal in their bodies from a surgical intervention or working in metalwork, or is unsure if metal is present in their bodies, etc.).